Dickkopf‐1 (Dkk‐1) and sclerostin, two extracellular negative regulators of the Wnt/β‐catenin pathway, are considered as potential targets for bone anabolic anti‐osteoporosis therapy (Diarra et al, 2007; Fulciniti et al, 2009; Heath et al, 2009; Li et al, 2009; Ominsky et al, 2010). This evidence concerns the gene SOST and osteoporosis.